Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 7/20 | 0.51 |
| ▸ | DRD4 | P21917 | 5/20 | 0.51 |
| ▸ | IGF1R | P08069 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187557 | 0.89 | MEN1 (0.51) | ALDH1A1HTR1AMAPTGAARAD52 | |
| SCHEMBL5186020 | 0.88 | KCNH2 (0.51) | ALDH1A1HTR1AMAPTGAARAD52 | |
| SCHEMBL15872034 | 0.83 | ALDH1A1 (0.63) | ALDH1A1HTR1AMAPTDRD2DRD4 | |
| SCHEMBL11960837 | 0.81 | MAPT (0.69) | ALDH1A1HTR1AMAPTGAARAD52 | |
| SCHEMBL10730439 | 0.80 | ALDH1A1 (0.63) | ALDH1A1HTR1ADRD2HTR7MEN1 | |
| SCHEMBL3187550 | 0.80 | DRD2 (0.56) | ALDH1A1HTR1ADRD2DRD4IGF1R | |
| SCHEMBL7923952 | 0.79 | HTR1A (0.58) | ALDH1A1HTR1AMAPTGAADRD2 | |
| SCHEMBL5010587 | 0.79 | HTT (0.56) | ALDH1A1HTR1ADRD2DRD4IGF1R | |
| SCHEMBL14228584 | 0.79 | HTR7 (0.50) | HTR1AMAPTGAARAD52GFER | |
| SCHEMBL7597607 | 0.78 | MEN1 (0.67) | ALDH1A1HTR1AMAPTDRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757590-B1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INST SCI & TECH (KR) | 2009-12-02 | — | — | EP | disclosed |
| US-7544686-B2 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-06-09 | — | — | US | disclosed |
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2007-03-01 | — | — | US | disclosed |
| EP-1757590-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | Korea Institute of Science and Technology (KR) | 2007-02-28 | — | — | EP | disclosed |
| EP-1325917-B1 | Radiolabelled alkylamino-benzothiazole and -benzoxazole derivatives and their use as D4 ligands | JANSSEN PHARMACEUTICA NV (BE) | 2007-01-03 | — | — | EP | disclosed |
| EP-0912533-B1 | ALKYLAMINOBENZOTHIAZOLE AND -BENZOXAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2004-09-29 | — | — | EP | disclosed |
| EP-1325917-A1 | Radiolabelled alkylamino-benzothiazole and -benzoxazole derivatives and their use as D4 ligands | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-07-09 | — | — | EP | disclosed |
| US-6224849-B1 | Alkylaminobenzothiazole and-benzoxazole derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-05-01 | — | — | US | disclosed |
| EP-0912533-A1 | ALKYLAMINOBENZOTHIAZOLE AND -BENZOXAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997043271-A1 | ALKYLAMINOBENZOTHIAZOLE AND -BENZOXAZOLE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049604-A1 | Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof | CACNA1I, CACNA1G, CACNA1H | ALDH1A1 2701/4885HTR1A 1924/4885MAPT 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.